Nicholas Singer has been named as a new member of Brooklyn ImmunoTherapeutics' Board of Directors.
As IntegriCo continues to expand and restructure as a company, Nicholas Singer was named executive chairman responsible for day-to-day management. He expresses his excitement for future growth and benefit for the environment.
Westchester County lawmakers approved a new contract for a company to manage Playland on Monday, after the effort to dissolve the old contract fizzled. The county Board of Legislators voted 13-4 to give a new contract to Standard Amusements. Under the new deal, Standard would take over day-to-day operations of the park on Dec. 1.
Brooklyn ImmunoTherapeutics, Inc., a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the completion of the reverse merger with NTN Buzztime, Inc. Brooklyn will focus on the advancement of IRX-2, its cytokine-based compound for the treatment of various cancers, as well as opportunities in the area of gene editing/cell therapy through its option agreement with Factor Bioscience/Novellus.
"We're excited about our leading position in new markets with substantial future growth opportunities," said Singer. "We have established trust with our vendors and customers, and positioned the business on strong financial footing that will serve as a springboard for continued growth while continuing to benefit the environment."
